Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs
GM Dubowchik, MA Walker - Pharmacology & therapeutics, 1999 - Elsevier
This review is a survey of various approaches to targeting cytotoxic anticancer drugs to
tumors primarily through biomolecules expressed by cancer cells or associated vasculature …
tumors primarily through biomolecules expressed by cancer cells or associated vasculature …
Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action
M Manoharan - Antisense and Nucleic Acid Drug Development, 2002 - liebertpub.com
This review summarizes the effect of conjugating small molecules and large
biomacromolecules to antisense oligonucleotides to improve their therapeutic potential. In …
biomacromolecules to antisense oligonucleotides to improve their therapeutic potential. In …
Engineered nucleic acids encoding a modified erythropoietin and their expression
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
46147671&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
46147671&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
Terminally modified RNA
T Chakraborty, S Bancel, SG Hoge, A Roy… - US Patent …, 2017 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49447811&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
49447811&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
Engineered nucleic acids and methods of use thereof
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C (= O) C (NC (= O)
C (CCC (N)= O) NC (= O) C (CCC (O)= O) NC (= O) C (C (C) C) NC (= O) C (NC (= O) CN) C …
C (CCC (N)= O) NC (= O) C (CCC (O)= O) NC (= O) C (C (C) C) NC (= O) C (NC (= O) CN) C …
Modified polynucleotides for the production of biologics and proteins associated with human disease
S Bancel, T Chakraborty, A De Fougerolles… - US Patent …, 2015 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
Modified polynucleotides for the production of secreted proteins
T Chakraborty, A De Fougerolles - US Patent 9,192,651, 2015 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions
F Von Der Mülbe, I Hoerr, S Pascolo - US Patent 10,188,748, 2019 - Google Patents
The present invention relates to a pharmaceutical composi tion comprising a modified
mRNA that is stabilized by sequence modifications and optimized for translation. The …
mRNA that is stabilized by sequence modifications and optimized for translation. The …
In vivo production of proteins
S Bancel, T Chakraborty, A De Fougerolles… - US Patent …, 2015 - Google Patents
2013-03-19 Assigned to modeRNA Therapeutics reassignment modeRNA Therapeutics
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors …
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors …
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
T Chakraborty, A De Fougerolles - US Patent 9,303,079, 2016 - Google Patents
2013-03-19 Assigned to modeRNA Therapeutics reassignment modeRNA Therapeutics
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors …
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors …